Immunopathological evaluation of recombinant mycobacterial antigen Hsp65 expressed in Lactococcus lactis as a novel vaccine candidate

Document Type : Full paper (Original article)

Authors

1 Ph.D. Student in Veterinary Sciences, Molecular Biology Laboratory, Veterinary Sciences Research Institute, Autonomous University of Baja California, Mexicali, Baja California, 21388, Mexico

2 MSc Student in Veterinary Sciences, Molecular Biology Laboratory, Veterinary Sciences Research Institute, Autonomous University of Baja California, Mexicali, Baja California, 21388, Mexico

3 MSc, Molecular Biology Laboratory, Veterinary Sciences Research Institute, Autonomous University of Baja California, Mexicali, Baja California, 21388, Mexico

4 Molecular Biology Laboratory, Veterinary Sciences Research Institute, Autonomous University of Baja California, Mexicali, Baja California, 21388, Mexico

Abstract

Bovine tuberculosis (TBB) is a zoonotic disease distributed worldwide and is of great importance for public health and the livestock industry. Several experimental vaccines against this disease have been evaluated in recent years, yielding varying results. An example is the Bacillus Calmette-Guérin (BCG) vaccine, which has been used extensively in humans and tested in cattle showing mixed results related to protection (0-80%) against Mycobacterium bovis. In this study, we used the food-grade bacterium Lactococcus lactis as an expression system for production of mycobacterial protein Hsp65. For this purpose, the construction of a replicable plasmid in strain NZ9000 L. lactis (pVElepr) was conducted, which expressed the Mycobacterium leprae Hsp65 antigen, and was recognized by traded anti-Hsp65 antibodies. The strain NZ9000-pVElepr was applied to calves that were negative to tuberculin test and the immune response was monitored. The results showed that immune response was not significantly increased in calves with NZ9000-pVElepr with respect to control groups, and no injury was observed in any lung or lymph of the calves. Finally, this study suggest that the recombinant NZ9000 strain of L. lactis may protect against the development of M. bovis infection, although studies with longer exposure to this pathogen are necessary to conclude the matter.

Keywords

References

Asociación Médica Mundial (2005). Manual de ética médica.
Azevedo, MS; Rocha, CS; Electo, N; Pontes, DS; Molfetta, JB; Goncalves, ED; Azevedo, V; Silva, CL and Miyoshi, A (2012). Cytoplasmic and extracelular expression of pharmaceutical-grade mycobacterial 65-kDa heat shock protein in Lactococcus lactis. J. Genet. Mol. Res., 11: 1146-1157.
Bahey-El-Din, M; Gahan, CG and Griffin, BT (2010). Lactococcus lactis as a cell factor for delivery of therapeutic proteins. J. Curr. Gene Ther. 10: 34-45.
Bermúdez-Humarán, LG; Langella, P; Miyoshi, A; Gruss, A; Tamez, GR; Montes de Oca-Luna, R and Le, LY (2002). Production of human papillomavirus type 16 E7 protein in Lactococcus lactis. J. App. Environm. Microbiol., 68: 917-922.
Bermúdez-Humarán, LG; Pascale, K; Chatel, JM and Langella, P (2011). Lactococci and Lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb. Cell Fact. (Suppl. 1), 10: S4.
Bolontin, A; Wincker, P; Mauger, S; Jaillon, O; Malarme, K; Weissenbach, J; Ehrlich, SD and Sorokin, A (2001). The complete genome sequence of the lactic acid bacterium Lactococcus lactis spp. lactis IL1403. J. Genome Res. 11: 731-753.
Buddle, BM; de Lisle, GW; Pfeiffer, A and Aldwell, FE (1995). Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG. J. Vaccine. 13: 1123-1130.
Buddle, BM; Wedlock, DN; Parlane, NA; Corner, LA; de Lisle, GW and Skinner, MA (2003). Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. J. Infect. Immun., 71: 6411-6419.
Cortes-Perez, NG; Bermudez-Humaran, LG; Le, LY; Rodriguez-Padilla, C; Gruss, A; Saucedo-Cárdenas, O; Langella, P and Montes-de-Oca, LR (2003). Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. FEMS Microbiol. Lett., 229: 37-42.
Dieye, Y; Usai, S; Clier, F; Gruss, A and Piard, JC (2001). Design of a protein-targeting system for lactic acid bacteria. J. Bacteriol., 183: 4157-4166.
Laemmli, UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. J. Nature. 227: 680-685.
Lei, H; Sheng, Z; Ding, Q; Chen, J; Wei, X; Lam, DMK and Xu, Y (2011). Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin. Vaccine Immunol., 18: 1046-1051.
Lima, KM; Dos Santos, SA; Santos, RR; Brandâo, IT; Rodrigues, JM and Silva, CL (2003). Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo. J. Vaccine. 22: 49-56.
Lopez-Valencia, G; Renteria-Evangelista, T; Williams, JJ; Licea-Navarro, A; Mora-Valle, A and Medina-Basulto, G (2009). Field evaluation of the protective efficacy of Mycobacterium bovis BCG vaccine against bovine tuberculosis. J. Res. Vet. Sci., 88: 44-49.
Lowrie, DB (2006). DNA vaccines for therapy of tuberculosis: where are we now? J. Vaccine. 24: 1983-1989.
Lowrie, DB; Tascon, RE; Bonato, VL; Lima, VM; Faccioli, LH; Stravropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K and Silva, CL (1999). Therapy of tuberculosis in mice by DNA vaccination. J. Nature. 400: 269-271.
Lyashchenko, K; Whelan, OA; Greenwald, R; Pollock, JM; Andersen, P; Hewinson, RG and Vordermeier, HM (2004). Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with Mycobacterium bovis BCG and infected with M. bovis. J. Infect. Immun., 72: 2462-2467.
Martínez-Vidal, C; Hori, S; De la Mora, A; Bermúdez, RM; Rentería, TB; López, G; Galván, LJ and Medina, GE (2011). VNTR for genotyping of Mycobacterium bovis isolates from cattle slaughtered in Baja California, Mexico. J. Rev. Mex. Cienc. Pecu., 2: 393-401.
Mustafa, AS; Lundin, KEA; Meloen, RH; Shinnick, TM and Oftung, F (1999). Identification of promiscuous epitopes from the mycobacterial 65-kilodalton heat shock protein recognized by human CD4+ T cells of the Mycobacterium leprae memory repertoire. Infect. Immun., 67: 5683-5689.
NOM-031-ZOO-1995 (NORMA, Oficial Mexicana). Campaña nacional contra la tuberculosis bovina (Mycobacterium bovis).
Nouaille, S; Ribeiro, LA; Miyoshi, A; Pontes, D; Le, LY; Oliveira, SC; Langella, P and Azevedo, V (2003). Heterologous protein production and delivery systems for Lactococcus lactis. J. Genet. Mol. Res., 2: 102-111.
Sambrook, J and Russell, DW (2001). Molecular cloning a laboratory manual. 3rd Edn., New York, USA, Cold Spring Harbor Laboratory Press. PP: 15.35.
Santos, PD; Pacheco, AMS; Chatel, JM; Langella, P; Azevedo, V and Miyoshi, A (2011). Lactoccocus lactis as a live vector: heterologous protein production and DNA delivery systems. J. Protein Expr. Purif., 79: 165-175.
Thoen, CO; Steele, JH and Gilsdorf, MJ (2006). Mycobacterium bovis infection in animals and humans. 2nd Edn., Iowa, USA, Blackwell Publishing. PP: 34-49.

Files

Share

How to cite

Statistics